-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Blueprint Medicines Corp quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q1 2025.
- Blueprint Medicines Corp Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $789K, a 338% increase year-over-year.
- Blueprint Medicines Corp Income Tax Expense (Benefit) for the twelve months ending March 31, 2025 was $1.84M, a 192% increase year-over-year.
- Blueprint Medicines Corp annual Income Tax Expense (Benefit) for 2024 was $1.23M, a 26.7% increase from 2023.
- Blueprint Medicines Corp annual Income Tax Expense (Benefit) for 2023 was $968K, a 81.5% decline from 2022.
- Blueprint Medicines Corp annual Income Tax Expense (Benefit) for 2022 was $5.24M, a 74.5% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)